<DOC>
	<DOC>NCT02422563</DOC>
	<brief_summary>Randomized comparison of neoadjuvant chemotherapy followed by radical hysterectomy with pelvic Â± para-aortic lymphonodectomy (LNE) versus primary cisplatin-based chemo-radiation in patients with cervical cancer FIGO IB2 and IIB.</brief_summary>
	<brief_title>NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB</brief_title>
	<detailed_description>The optimal treatment for patients with cervical cancer on FIGO stage IB2 and IIB is controversial. There is no randomized comparison of a dose-dense NACT (TP or TIP-schedule) followed by hysterectomy and LNE (investigational Arm A) versus primary chemo-radiation (standard arm B). Primary endpoint is the DFS at 5 years, secondary endpoints local control at 5 years, OS at 5 years, QOL, questionnaires on sexual activity/QOL.</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>&gt;18 years cervical cancer FIGO IB2, IIB, squamous cell, adeno or adenosquamous cell carcinoma informed consent small cell/neuroendocrine component previous radiation, previous cancer pregnancy HIV severe comorbidities</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>FIGO IB2, FIGO IIB</keyword>
	<keyword>chemo-radiation</keyword>
	<keyword>dose dense chemotherapy</keyword>
	<keyword>cisplatin</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
	<keyword>ifosfamide</keyword>
</DOC>